MPI Research invites you to stop by Booth #718 for a morning “jolt” of espresso or cappuccino, during the Society of Toxicology Meeting in Nashville, Tennessee at the Opryland Convention Center March 18 - 20, 2001. We are excited about our growth in the industry and would like to share our new services and capabilities, including animal efficacy studies for cardiovascular, stroke, diabetes, renal failure, obesity, angiogenesis models, among others. Stop by our new booth to meet two of our new Senior Study Directors, Dr. Steven Godin and Dr. Stephen Frantz. Dr. Richard Briscoe will present “ICH Guideline Implications for Safety Pharmacology” daily. All of our toxicologists in attendance will be ready to discuss your toxicology needs.

James Laveglia, Ph.D., Executive Vice President and Director of Research, commented, “The MPI team is very enthusiastic about our company and capability enhancements. Please stop by our new booth so we can share our new capabilities and excitement with you.” For more information on MPI Research, visit our website, www.mpiresearch.com.

MPI Research exists to provide non-clinical research that meets the requirements of pharmaceutical, animal health and chemical companies as well as governmental agencies, as they develop products for a healthier world. MPI employees specialize in a wide variety of scientific disciplines including toxicology, pharmacology, metabolism, pathology, clinical pathology, reproductive and developmental biology, veterinary science, neuroscience, analytical chemistry, computer science, regulatory science, and statistics.

Home | News